World-Class Care with Heart

Pediatric Hematology Oncology Research

This listing changes frequently.  For more information about the trials we have available, please contact us at (551) 996-5627 or via e-mail

Burton Appel, MD

AALL05B1:  Children’s Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Burton Appel, MD

AALL08B1:  Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Pro00001704 / III
Burton Appel, MD

AALL0932:  Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)
Pro00002711 / III
Burton Appel, MD

AALL1131:  A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
Burton Appel, MD

AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
Pro00005494 / III
Burton Appel, MD

AALL1331, Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Burton Appel, MD

AAML08B1:  Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)
Pro00002422 / III
Burton Appel, MD

AAML1031:  A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND# 114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
Michael B. Harris, MD

ABTR01B1:  A children’s Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
Michael B. Harris, MD

ABTR04B1:  Establishing Continuous Cell Lines and xenografts from Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Pro00003215 / II
Cindy Steele, MD

ACCL0922 (SCUSF 0901):  A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor
Pro00002274 / III
Steven Diamond, MD

ACCL0933:  A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Pro00002442 / III
Steven Diamond, MD

ACCL0934:  A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation(HSCT)
Pro00003134 / III
Burton Appel, MD

ACCL1033: A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Carlene Cord, APN

ACCL1034:  Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)

Pro00004268 / III
Jennifer Krajewski, MD

ACCL1131: A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)
Michael B. Harris, MD

ACCRN07:  Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
Cindy Steele, MD

ACNS02B3:  A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
04.02.095B / III
Cindy Steele, MD

ACNS0331:  A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 G7 and Chemotherapy In Children With Newly Diagnosed Standard Risk Medulloblastoma:  A Phase III Double Randomized Trial
07.02.070C /III
Burton Appel, MD

ACNS0332:  Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Pro00000844 / III
Alfred P. Gillio, MD

ACNS0334:  A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate
Pro00002116 / II
Michael B. Harris, MD

ACNS0821:Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
Pro00001761 / III
Frances Flug, MD

ACNS0831:  Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
Pro00003805 / II
Steven Diamond, MD

ACNS1022:  A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas
Pro00003273 / II
Frances Flug, MD

ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
Pro00004886 / II
Michael B. Harris, MD

ACNS1221:  A Phase II Study For The Treatment Of Non-Metastatic Desmoplastic Medulloblastoma In Children Less Than 4 Years of Age
Michael B. Harris, MD

AEWS07B1:  A Children’s Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens
Pro00001987 / III
Michael B. Harris, MD

AEWS1031:  A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
Pro00001203 / III
Michael B. Harris, MD

AHEP0731:  Treatment of Children with All Stages of Hepatoblastoma
Burton Appel, MD

AHOD04B1:  Hodgkin Disease Banking Study
Michael B. Harris, MD

ALTE03N1:  Key Adverse Events after Childhood Cancer
Michael B. Harris, MD
ALTE05N1:  Umbrella Long-term Follow-up Protocol
Anne Farrar-Anton, PhD

ALTE07C1:  Neuropsychological, Social, Emotional and Behavioral Outcomes in Children With Cancer
Michael B. Harris, MD

ALTE11C1:  Longitudinal Assessment of Ovarian Reserve in Adolescents With Lymphoma
Michael B. Harris, MD

ALTE11C2:  Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy
02.02.015 / III
Burton Appel, MD

ANBL0032:  Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
Burton Appel, MD

ANBL00B1:  Neuroblastoma Classification Biology Studies
Pro00004004 / Pilot
Michael B. Harris, MD

ANBL12P1: Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma
Pro00003808 / II
Burton Appel, MD

ANBL1221:  A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
Michael B. Harris, MD

ANBL1232: Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients With Non-High Risk Neuroblastoma
Burton Appel, MD

ANHL04B1:  Rare Cutaneous Non-Hodgkin Lymphoma Registry
Pro00003271 / III
Burton Appel, MD

ANHL1131:  Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma NHL or Mature B-cell Leukemia B- AL:  Evaluation of Rituximab Efficacy and Safety in High Risk Patients
Pro00004838 / II
Burton Appel, MD

ANHL12P1:  A Randomized Phase II study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117
Michael B. Harris, MD
AOST06B1:  A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
Pro00005408 / II
Michael B. Harris, MD

AOST1322, Phase II Study of Eribulin (IND# 122686, NSC# 707389) in Recurrent or Refractory Osteosarcoma
Burton Appel, MD

AREN03B2:  Renal Tumors Classification, Biology, and Banking Study
Pro00001304 / III
Burton Appel, MD

AREN0534:  Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor
Pro00004232 / II
Jennifer Krajewski, MD

ASCT1221: A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML)
Burton Appel, MD

D9902:  A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
Burton Appel, MD

9442:  National Wilms Tumor Late Effects Study
Frances Flug, MD

AT/RT:  Registry for Central Nervous System Atypical Teratoid/Rhabdoid Tumor
Pro00003350 / IIb
Cindy Steele, MD

MK0517-029 A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with Emetogenic Chemotherapy
Steven Diamond, MD

SCNIR:  Severe Chronic Neutropenia International Registry

best-hospitals-cardiology    high-performing-indicator-heartfailure    high-performing-indicator-heartbypass     HG_Americas_50_Best_Award_Image_2014      HG_Americas_100_Best_Stroke_Care_Award_Image_2014        HG_Americas_100_Best_Pulmonary_Care_Award_Image_2014     red-bulllgbt      tkc_homepagelogo-2

Translation service provided by Google. Hackensack University Medical Center is not responsible for the accuracy of translation or any other
aspect of service provided by the GoogleTranslate tool. Users should not make medical decisions without first consulting
with their physician.
Site Map|Privacy Policy|Media Center
©2017 Hackensack University Medical Center. All rights reserved.
close (X)